GlassScriptPhysician profile
Marissa Stewart
NPI 1316258437
$9,249.49
in general payments reported to CMS, 2019-2025
46 companies · $164 in 2025
The $164 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,349 · 2020: $1,574 · 2021: $1,922 · 2022: $2,041 · 2023: $2,199 · 2025: $164.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,363.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,363.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,231.19 | 2019-2023 | Ubrelvy, Vraylar, Qulipta |
| Novo Nordisk INC | $1,190.68 | 2019-2023 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $1,083.48 | 2019-2023 | Mounjaro, Jardiance, Emgality |
| Pfizer INC. | $718.45 | 2019-2023 | |
| Amgen INC. | $672.80 | 2019-2023 | Otezla, Repatha, Prolia |
| Astrazeneca Pharmaceuticals LP | $637.97 | 2019-2023 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $445.55 | 2019-2023 | Spiriva Respimat, Jardiance |
| Astellas Pharma US INC | $291.95 | 2019-2023 | Veozah, Myrbetriq |
| Corium, LLC | $237.88 | 2022-2023 | Azstarys |
| Supernus Pharmaceuticals, INC. | $233.19 | 2019-2023 | Qelbree |
| Sanofi-Aventis U.S. LLC | $213.18 | 2019-2023 | |
| Allergan, INC. | $202.71 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $176.62 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $168.52 | 2022 | |
| Amarin Pharma, INC. | $158.02 | 2020-2021 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marissa Stewart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.